MOVE Medacta Group

Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution

Medacta Group SA / Key word(s): Market Launch
Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution

21.09.2022 / 19:00 CET/CEST


 

Media release


Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution

CASTEL SAN PIETRO, Switzerland, September 21, 2022 – Medacta announced today the completion of the first revision surgeries in the US using , the game-changing technology for streamlining and guiding total knee revision surgeries where even highly experienced surgeons can face complex and time-consuming procedures.

One of the most challenging aspects of revision knee arthroplasty is the detection of anatomic landmarks for proper positioning of the new implant. I found the MyKnee R preoperative planning capability incredibly useful in eliminating many of the surprises that we encounter intraoperatively,” says Jay Patel, D.O., at Atlanta Orthopaedic Institute, Atlanta, GA, USA.

MyKnee R provides personalized 3D interactive preoperative planning and a set of 3D-printed guide blocks. These guides are placed directly on the existing primary implant in situ to guide the placement of new implants from Medacta’s comprehensive knee portfolio, ranging from a lower level of constraint ( and ) to semi- and fully constrained solutions ( and ). These implants are part of a synergistic system that allows for intraoperative flexibility and are available with the ceramic-like coating, an option designed for reduced metal ion release.

With MyKnee R, it is also possible to plan the position of the GMK System’s revision options (i.e., cones, extension stems, offsets, and augments), addressing the high variation in knee revision scenarios with maximized versatility.

“Revision TKA can present many intraoperative surgical challenges, primarily due to substantial bone loss at the distal femur and/or proximal tibia. The unique ability to preoperatively plan and, most importantly, visualize the positioning, orientation, and sizing of revision constructs with MyKnee R has been extremely helpful in anticipating, evaluating, and treating some of these intraoperative hurdles,” says Kris J. Alden, M.D., Ph.D., at the Illinois Bone & Joint Institute, USA.

MyKnee R is part of the , Medacta’s advanced network of digital solutions designed to improve patient outcomes and healthcare efficiency. Together with a comprehensive implant portfolio, from unicompartmental to hinged systems, MySolutions empowers Medacta’s holistic approach to personalized medicine, bringing value at every step throughout the entire patient journey.

MyKnee R is also supported by the comprehensive, tailored educational offering provided by the . With an international network of expert surgeons, the M.O.R.E. Institute is at the forefront of education on total knee replacement techniques and products with personalized high-level educational pathways. With Medacta the surgeon is never alone.

Discover more about and .

 

 

 

Contact

Medacta International SA

Gianluca Olgiati

Senior Director Global Marketing

Phone: 0

 

About Medacta

Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon experts globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

 

 


Additional features:

File:


End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone:
E-mail:
Internet:
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1447661

 
End of News EQS News Service

1447661  21.09.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1447661&application_name=news&site_id=research_pool
EN
21/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medacta Group

Maria Vara
  • Maria Vara

Medacta: model update - Buy rating reiterated, unchanged CHF160 PT

We update our model following the publication of the company's annual report. No changes have been applied to our revenue forecast as FY 2024 results and 2025 guidance are aligned with our estimates. On the P&L, we have softened our S&M expenses expectation as these stood more towards 35.5%

 PRESS RELEASE

Medacta publishes 2025 Annual General Meeting invitation

Medacta Group SA / Key word(s): AGMEGM Medacta publishes 2025 Annual General Meeting invitation 08.04.2025 / 10:00 CET/CEST Press Release                     Medacta publishes 2025 Annual General Meeting invitation  CASTEL SAN PIETRO, 8 April 2025 – Medacta Group SA (“Medacta”, SIX:MOVE) published today the invitation to the Annual General Meeting (“AGM”) which will take place on Wednesday, 7 May 2025 at 11.00 a.m. at the Group premises in Via alla Rossa 6, Rancate, Switzerland. Shareholders can register to attend the Annual General Meeting in person but will also be abl...

Maria Vara
  • Maria Vara

Medacta: Exceptional FY2024 to fuel sustainable growth, adj. EBITDA hi...

Medacta reported preliminary unaudited FY 2024 revenue in early February; hence, the EUR590.6m figure was not a surprise. Nonetheless, we may highlight again that all four business lines delivered above the market growth with double-digit cc gains with a broad base geographical contribution. Gross

Maria Vara
  • Maria Vara

Medacta: expanding SportsMed footprint with Parcus Medical acquisition

Medacta expands its SportMeds footprint by acquiring Parcus Medical, a distinguished player with a diverse product family in sports medicine spanning the shoulder, knee, hip, and foot & ankle, with FY2024 unaudited revenues of USD16m. The acquisition not only expands Medacta's offering but also

 PRESS RELEASE

Medacta Group SA acquires Parcus Medical to accelerate expansion in Sp...

Medacta Group SA / Key word(s): Acquisition/Acquisition Medacta Group SA acquires Parcus Medical to accelerate expansion in Sportsmed 07.03.2025 / 07:00 CET/CEST Press Release   Medacta Group SA acquires Parcus Medical to accelerate expansion in Sportsmed Specialist provider of sports medicine and arthroscopy solutions Excellently complementing Medacta’s portfolio in sports medicine Gaining access to additional global sales channels and customers Increasing presence in the fast-growing Ambulatory Surgery Centre US market CASTEL SAN PIETRO, 07 March 2025 – Medacta Grou...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch